Background: The aim of this study was to find that if the red cell distribution width (RDW) or hemoglobin (Hb) level variations had prognostic value in stage III colorectal cancer patients treated with operation and adjuvant chemotherapy. Methods: One hundred and twenty-two patients were included in this retrospective study. All were diagnosed and restaged as stage III colorectal cancer in Sichuan Cancer Hospital according to the AJCC Cancer Staging Manual, 8 th edition, 2018. The patients received R0 resection before adjuvant chemotherapy. The baseline information, routine blood examination data, pathological outcome and prognostic stature was retracted from the database. Receiver operating characteristic (ROC) curve analysis was utilized to determine the cut-off value, while the survival analyses were performed with Kaplan-Meier curve, the log-rank test and the Cox regression analysis. Results: The chemotherapy-associated hemoglobin change (change between the pre-and post-chemotherapy hemoglobin levels)
was identified to be associated with the metastasis (P=0.030). The optimal cut-off point was calculated to be -9.5 by the ROC curve of the hemoglobin change, while the area under the curve was 0.648 (95% CI: 0.524-0.772). The results showed that patients with larger hemoglobin decrease had significantly worse disease free survival (DFS) than those with smaller decrease (P=0.020). Factors associated with DFS in uni-variate COX regression analysis were the number of harvested lymph nodes (P=0.040) and the perineural invasion (P=0.020). The peri-chemotherapy change of hemoglobin level was estimated to have significant effect on patient survival (P=0.010). Conclusions: We concluded that chemotherapy-associated Hb change (change between the pre-and postchemotherapy) was a DFS prognostic factor for the stage III colorectal cancer patients who underwent operation and adjuvant chemotherapy. 3 Background Operation and adjuvant chemotherapy is the standard treatment for operative stage III patients [1, 2] . However, there are limited prognostic factors can be utilized to predict the survival of those patients, despite of traditional pathological sub-stage and indications of poorer prognosis. Bio-markers, such as ras or B-raf mutation,micro-satellite instability etc., have been recommended as effective evidence, while there are few publications confirmed their predictive capability when taking chemotherapy in consideration.
Red blood cell volume distribution width (RDW), which is the quantitative measurement of heterogeneity of the red blood cell size, can reflect impaired erythropoiesis and abnormal red blood cell survival. Although the early studies focused on the correlation between RDW and benign and chronic disease, recent publications have indicated its potential utilization in malignant tumors. Seretis [3] reported that RDW was related to the metastasis of breast cancer, and Lippi [4] concluded that RDW value was related to the stage of lung cancer. The information suggested the RDW might be utilized as prognostic factor, since the relationship between RDW and clinical characteristic of malignancies.
Several publications indicated certain values of hemoglobin or RDW in colorectal cancers.
Yang [5] found that red blood cell distribution width was closely related to colorectal cancer metastasis. Wei [6] reported that chemotherapy-associated hemoglobin might be a prognostic bio-marker. Zhang [7] claimed that elevated red blood cell volume distribution width-the change of diversity (RDW-CV) might be an independent predictive factor in resectable rectal cancer patients. However, few articles focused on the change of red Hemoglobin, RDW-CV as well as RDW-SD (red blood cell volume distribution widthstandard deviation), with four groups data included pre-and post-operation, and pre-and post-chemotherapy for each index, were also collected. The data of pre-operative timing was determined as the day before surgery while post-operative was 48-72 hours after surgery. The data of the pre-chemotherapy was also determined as the day before the first chemotherapy while post-chemotherapy was the day after final treatment. 
Follow-up

Results
Characteristics of the study population
In this study, one hundred and twenty two CRC stage III patients' information was gathered from a prospectively collected database. All patients received R0 operation from April 2014 to January 2017, followed by adjuvant chemotherapy. There were 69 (56.6%) males and 53 (43.4%) females with a median follow-up time of 42 months (12 to 59 months). The mean age ± standard deviation (SD) of patients at the time of operation was 54.75±11.28 years. The patients' demographic information is presented (Table 1) . In COX regression multivariate analysis, the Hb changes (pre-and post-chemotherapy) remained as a statistically significant risk factor for the tumor metastasis. The higher Hb changes (pre-and post-chemotherapy) was associated with worse DFS (P=0.010).
Changes in red cell distribution width and Hb values during therapy
However, there was no correlation between Hb changes (pre-operation and post-chemotherapy) and the tumor recurrence. The results of the statistical calculations on COX regression multivariate analysis was presented (Table 3 ). In addition, the harvested lymph nodes number (P=0.040) and the perineural invasion (P=0.020) were significant prognostic factor for the DFS.
Discussion
Anemia is a common comorbidity in CRC patients, while Hb level changes can be observed in those who received surgery and adjuvant chemotherapy. In our study, we find that Hb level changes, especially the changes after the whole treatment, may be related to the prognosis of stage III CRC patients. After Cox multivariate analysis, the change between pre-and post-adjuvant chemotherapy remains as an individual risk factor for locally advanced CRC patients. The analysis also confirms the harvested lymph nodes number and the perineural invasion are independent prognostic factors, which indicated the accuracy of the study. Amount of studies reported the level of Hb is related to the survival of malignant tumor patients. However, most of the studies focused on the preoperative anemia and its relationship with prognosis [8] [9] [10] . Current studies indicate that pre-operative and postoperative Hb levels are related to the survival of malignant patients received radical resection [11] . The potential mechanism is estimated to be the relation between low Hb levels and hypoxia status of malignant tissues and the matrix [12] . Hypoxia sensitive gene, such as hypoxia-induced factors (HIFs) , Snail gene, FRFG3 and OCT4 may be involved in the mechanism [13] [14] [15] [16] . However, tumor induced anemia, caused by chronic blood loss, should be regarded as a significant influence on the variation of Hb levels, which can be intervened by surgery and adjuvant chemotherapy.
Wei also reported that Hb changes after adjuvant chemotherapy is related to the prognosis of CRC patients [17] . The point is stage II and III patients are all confounded in that study and receive FOLFOX regimen treatment, while IDEAL study suggests only stage II CRC patients with high risks are recommended to be adjuvantly treated. The study focused on proving chemotherapy indicated anemia is a significant prognostic factor.
Above all, our current study indicates the prognostic significance of Hb change during the treatment in stage III CRC patients. Hb test (blood count) is a non-invasive and mature routine blood test, which is economical, effective, simple and convenient. It is also universally accepted as routine test for post-operative monitoring. Therefore, Hb test has the potential of being predictor of survival for locally advanced patients who receiving adjuvant treatment. However, further prospective studies, especially studies with interventions on Hb level, are needed to confirm the accuracy and effectiveness of the index.
During our research periodicity, no control study with intervention, such as ferralia supplement treatment, was reported. We expect related large-sized prospective studies will reveal whether this potential trend can be weakened or even reversed.
Conclusions
Hemoglobin level changes between before initiation of adjuvant chemotherapy and after the whole treatment may be a potential predictor of survival in stage III CRC patients. 
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